MedPath

Advanced Protein-based Program for Effective Treatment of Appetite Regulation and Obesity

Not Applicable
Completed
Conditions
Appetite and General Nutritional Disorders
Registration Number
NCT07104461
Lead Sponsor
University of Westminster
Brief Summary

INTRODUCTION: Obesity is a global epidemic, with over 2.5 billion adults being classified as overweight and 890 million of these classified as obese. Overweight and obesity are the 5th cause of mortality globally, with an estimated 2.8 million related deaths among adults. The rising prevalence of obesity in adults is leading to a rise in the prevalence of type 2 diabetes, with an estimated 462 million individuals affected globally. At present, the most effective non-surgical obesity treatments offered by the National Health Service (NHS) are the subcutaneously administered GLP-1 receptor agonists. However, they may present potentially serious side effects following short-term use, and there are still uncertainties around long-term use side effects. Therefore, a dietary approach to weight loss or maintenance seems preferable.

Increasing protein intake is a commonly applied nutritional approach to appetite regulation. The increase in protein intake is often achieved by supplementation, using proteins isolated from dairy, such as whey and casein. However, with more individuals following plant-based diets over recent years, the interest in plant-based protein supplements has increased. While dairy-based proteins are well-characterised, the appetite regulatory characteristics of plant-based proteins have not yet been fully elucidated.

The main aim of this study is to investigate the effects of protein-enriched food items on appetite regulation compared to a standard carbohydrate-rich meal. Furthermore, this study will investigate whether there are any differences in appetite-related hormonal responses to a plant protein-containing meal replacement shake (containing rice and pea protein) or a potato protein-enriched standard carbohydrate-based meal compared to a whey protein-enriched standard carbohydrate-based meal.

Detailed Description

Intervention study with four treatment groups in a randomised, single-blind, quadruple crossover design.

Healthy male participants (between the ages of 18 to 50 years) will receive four different isocaloric intervention meals with the same mass, on separate visit days, following a minimum of 8 hours overnight fast. The four meals will contain oat porridge prepared with coconut milk as a control, oat porridge prepared with coconut milk with added whey or potato protein isolates, and a complete meal replacement shake containing plant-based pea and rice proteins. The intervention meals will be followed by a standardised pasta-based ready meal after the 3-hour observation period. All participants will observe at least a two-day washout period between the differing treatments.

Biological samples (blood) will be collected at various times during the visit. Blood samples will be collected at baseline 0 min prior (T0), then at 30 min (T30), 60 min (T60), 120 min (T120) and 180 min (T180) after the intervention meal consumption.

In addition, pertinent questionnaires, Visual Analogue Scale \[VAS\] for assessing satiety and VAS for assessing intervention meals' perception and palatability will be collected. VAS for the assessment of satiety will be collected at T0, T30, T60, T120 and T180 and VAS assessing the perception and palatability of the intervention meals will be collected immediately following meal consumption.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
12
Inclusion Criteria
  • Males (18-50 years of age)
  • Lean and Overweight subjects (BMI 18.5 - 30 kg/m2)
  • Sedentary and physically active subjects
  • Healthy subjects
Exclusion Criteria
  • Female
  • <18, >50 years
  • Dieting
  • Consumption of >14 units of alcohol/week
  • Allergies to test foods/drinks
  • Illnesses or on medication (with a possible effect on taste and/or appetite)
  • Devices such as pacemakers
  • Smokers
  • Gastrointestinal disorders
  • Eating disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate and meal replacement shake on glucose levels (T30)Glucose measured 30 minutes post meal consumption

Glucose (mmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T60)Glucose measured 60 minutes post meal consumption

Glucose (mmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T120)Glucose measured 120 minutes post meal consumption

Glucose (mmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T180)Glucose measured 180 minutes post meal consumption

Glucose (mmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T30)Insulin measured 30 minutes post meal consumption

Insulin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T60)Insulin measured 160 minutes post meal consumption

Insulin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T120)Insulin measured 120 minutes post meal consumption

Insulin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T180)Insulin measured 180 minutes post meal consumption

Insulin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T30)Glucagon-like peptide 1 measured 30 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T60)Glucagon-like peptide 1 measured 60 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T120)Glucagon-like peptide 1 measured 120 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T180)Glucagon-like peptide 1 measured 180 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T30)Gastric inhibitory polypeptide measured 30 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T60)Gastric inhibitory polypeptide measured 60 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T120)Gastric inhibitory polypeptide measured 120 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T180)Gastric inhibitory polypeptide measured 180 minutes post meal consumption

Glucagon-like peptide 1 (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T30)Peptide tyrosine tyrosine measured 30 minutes post meal consumption

Peptide tyrosine tyrosine (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T60) Markers: peptide tyrosine tyrosine (pmol/L)Peptide tyrosine tyrosine measured 60 minutes post meal consumption

Peptide tyrosine tyrosine (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T120)Peptide tyrosine tyrosine measured 120 minutes post meal consumption

Peptide tyrosine tyrosine (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T180)Peptide tyrosine tyrosine measured 180 minutes post meal consumption

Peptide tyrosine tyrosine (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T30)Ghrelin measured 30 minutes post meal consumption

Ghrelin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T60)Ghrelin measured 60 minutes post meal consumption

Ghrelin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T120)Ghrelin measured 120 minutes post meal consumption

Ghrelin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T180)Ghrelin measured 180 minutes post meal consumption

Ghrelin (pmol/L)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T30)Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after meal consumption

Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T60)Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after meal consumption

Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T120)Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after meal consumption

Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T180)Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after meal consumption

Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

Secondary Outcome Measures
NameTimeMethod
To assess the perception of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake. Subjective analysis including Visual Analogue Scale for Perception and Palatability (VAS-P).VAS for Perception and Palatability collected immediately after meal consumption

Scores range from 0 to 100 (the higher the score, the lower the palatability)

To assess the effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on food intake ad libitum, 3 hours after the intervention meal consumption.Ad libitum food intake was assessed 3 hours post breakfast intervention meal consumption

Consecutive meal intake was assessed by measuring the weight in grams and calculating the energy content in Kcal of the food consumed.

Trial Locations

Locations (1)

Centre for Nutraceuticals School of Life Sciences, University of Westminster

🇬🇧

London, United Kingdom

Centre for Nutraceuticals School of Life Sciences, University of Westminster
🇬🇧London, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.